A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors-Reference-Cited by-同舟云学术

A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors

Published:2015-08-04 Issue:21 Volume:121 Page:3862-3868
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Grem Jean L.¹,Kos Mary E.²,Evande Ruby E.¹,Meza Jane L.³,Schwarz James K.¹

Affiliation:

1. Section of Oncology/Hematology, Department of Internal Medicine; University of Nebraska Medical Center; Omaha Nebraska

2. Early Clinical Trials Unit, Eppley Cancer Institute; University of Nebraska Medical Center; Omaha Nebraska

3. Department of Biostatistics, College of Public Health; University of Nebraska Medical Center; Omaha Nebraska

Funder

National Comprehensive Cancer Network / Allos Pharmaceuticals

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference42 articles.

1. Enhanced 5-fluorouracil nucleotide formation following methotrexate: biochemical explanation for drug synergism;Cadman;Science,1979

2. Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil;Bertino;Cancer Res,1977

3. Activity of sequential low-dose methotrexate and fluorouracil in advanced colorectal carcinoma. Attempt at correlation with tissue and blood levels of phosphoribosylpyrophosphate;Kemeny;J Clin Oncol,1984

4. The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer;Marsh;J Clin Oncol,1991

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacogenomics Testing in Phase I Oncology Clinical Trials: Constructive Criticism Is Warranted;Cancers;2022-02-23

2. Antifolate-based anticancer drugs;New Strategies Targeting Cancer Metabolism;2022

3. Predicting mucositis risk associated with cytotoxic cancer treatment regimens: rationale, complexity, and challenges;Current Opinion in Supportive & Palliative Care;2018-06